CAVE CREEK, AZ--(Marketwired - Apr 19, 2017) - Endexx Corporation (OTC PINK: EDXC), a provider of innovative phytonutrient-based food and nutritional products, announced that its Cannabidiol (CBD)-infused gourmet tea beverages are now available for purchase and is shipping to pre-order customers. The first batch of tea consists of 150 lbs., and produced over 28,000 tea bags.
Endexx's first product launch Third Eye Chai™, a masala chai tea, was a result of its license and distribution deal with The Mad Hatter Coffee & Tea Co. The collaboration offers a major opportunity to bring specific hemp and CBD-infused natural blends to the global health and whole foods markets, a major step for the cross-over markets valued at over $3 billion.
Todd Davis, CEO of Endexx, stated, "Our CBD-infused Chai, is primarily a wellness product that contains only the finest tea and herb ingredients and provides our customers with an enhanced tea experience. Although there is still a lot of education to be done on the health benefits of CBD, it has been proven to alleviate inflammation, muscle spasms, anxiety, epileptic seizures, and pain. Our licensing and partnership agreement with The Mad Hatter Coffee & Tea Co., will initially allow us to distribute our tea in the US, following with global distribution. This first product launch enables Endexx to generate licensing agreements with several large family owned conglomerates and distributors that have expressed strong interest in licensing our products, providing for additional revenue opportunities."
Endexx provides innovative inventory management and technology solutions. Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites®, is its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The company also has two technology products and services that launched in 2014 -- the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through "seed to sale" inventory management and an "End of Sale" technology integration. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to eventual federal mandates. The Autospense™ is a commercial grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com, www.endexx.com, www.m3hub.com.
Safe Harbor Notice
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.